Low-dose Molecular Breast Imaging: Comparison of Breast Cancer Detection Rate at Initial Screening and Two-year Follow-up

Stopped early · Not applicable

Conditions studied: Breast Cancer

In brief

The purpose of this research is to evaluate whether repeating a screening Molecular Breast Imaging (MBI) study two years after an initial screening MBI study further improves breast cancer detection in women with dense breast tissue.

Key facts

Study ID

NCT01723124

Run by

Mayo Clinic

People needed

228

Starts

2012-07-01

Expected to finish

2014-05-01

Last updated by the study team

2016-09-21

Who can join

Age: 40 and older, up to 80. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Past prior screening mammogram within the previous 11-24 months interpreted as heterogeneously dense or extremely dense and negative or benign [Breast Imaging Reporting and Data System (BI-RADS) Category 1 or 2]

You may not qualify if…

• Subjects will be excluded if they:
• Are unable to understand and sign the consent form
• Are pregnant or lactating
• Are physically unable to sit upright and still for 40 minutes
• Have self-reported signs or symptoms that may suggest breast cancer (palpable mass, bloody nipple discharge, axillary mass, etc.)
• Have had needle biopsy within 3 months, or breast surgery or radiation within 1 year prior to the study
• Are currently receiving chemotherapy or tamoxifen, raloxifene, or an aromatase inhibitor for adjuvant therapy or chemoprevention
• Have undergone bilateral mastectomy
• Have had a prior MBI within 20 months of scheduled study MBI.

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.